- Home
- KRMD vs PLX Comparison
KRMD vs PLX Comparison
Compare KRMD & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRMD | PLX |
|---|---|---|
| Founded | 1980 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.0M | 230.0M |
| IPO Year | 2019 | 1996 |
Fundamental Metrics
Financial Performance| Metric | KRMD | PLX |
|---|---|---|
| Price | $4.50 | $2.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $6.00 | ★ $12.00 |
| AVG Volume (30 Days) | 152.8K | ★ 1.2M |
| Earning Date | 04-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 56.67 | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | $33,646,463.00 | ★ $53,399,000.00 |
| Revenue This Year | $24.39 | $9.67 |
| Revenue Next Year | $18.14 | $23.86 |
| P/E Ratio | $90.20 | ★ N/A |
| Revenue Growth | ★ 17.98 | N/A |
| 52 Week Low | $1.87 | $1.34 |
| 52 Week High | $6.61 | $3.19 |
Technical Indicators
Market Signals| Indicator | KRMD | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 36.84 | 54.81 |
| Support Level | $3.80 | $1.39 |
| Resistance Level | $5.12 | $3.03 |
| Average True Range (ATR) | 0.22 | 0.14 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 8.82 | 49.59 |
Price Performance
Historical ComparisonAbout KRMD KORU Medical Systems Inc. (DE)
KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on mechanical infusion products, the FREEDOM Infusion Systems. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.